- Home
- CSTL
as 02-21-2025 4:00pm EST
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Upcoming Earnings Alert:
Get ready for potential market movements as Castle Biosciences Inc. CSTL prepares to release earnings report on 27 Feb 2025.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 848.1M | IPO Year: | 2019 |
| Target Price: | $40.33 | AVG Volume (30 days): | 349.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.97 - $35.84 | Next Earning Date: | 02-27-2025 |
| Revenue: | $311,878,000 | Revenue Growth: | 62.43% |
| Revenue Growth (this year): | 51.99% | Revenue Growth (next year): | -16.31% |
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BRADBURY DANIEL | CSTL | Director | Feb 5 '25 | Sell | $28.17 | 7,867 | $221,636.99 | 0 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jan 13 '25 | Sell | $28.55 | 2,565 | $71,902.93 | 60,588 | |
| BRADBURY DANIEL | CSTL | Director | Jan 6 '25 | Sell | $29.21 | 7,867 | $229,225.91 | 0 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Jan 6 '25 | Sell | $30.00 | 2,230 | $66,900.00 | 69,943 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Jan 6 '25 | Sell | $29.47 | 7,689 | $228,066.82 | 60,588 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 17 '24 | Sell | $28.55 | 9,364 | $265,357.92 | 60,588 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 13 '24 | Sell | $28.82 | 26,123 | $750,296.13 | 60,588 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 5 '24 | Sell | $31.35 | 5,127 | $160,741.70 | 60,588 | |
| BRADBURY DANIEL | CSTL | Director | Dec 3 '24 | Sell | $31.14 | 7,867 | $243,692.99 | 0 |
Latest Castle Biosciences Inc. News
CSTL Breaking Stock News: Dive into CSTL Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
Zacks
2 days ago
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?
Business Wire
10 days ago
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
Zacks
10 days ago
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock
Zacks
10 days ago
Castle Biosciences (CSTL) Upgraded to Buy: Here's Why
Zacks
10 days ago
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Zacks
15 days ago
Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review
Zacks
16 days ago
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
Compare CSTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.